One To Watch

Capricor Therapeutics

A San Diego-based biotechnology company pioneering cardiosphere-derived cell and exosome therapeutics for rare muscle and cardiac diseases, with FDA priority review for Deramiocel in Duchenne muscular dystrophy.

Company Overview

Capricor Therapeutics is a clinical-stage biotechnology company developing cell and exosome-based therapeutics for rare and serious diseases, with primary focus on Duchenne muscular dystrophy (DMD). Founded in 2005 and headquartered in San Diego, California, Capricor has established itself as a leader in regenerative medicine and cellular immunotherapy. The company's pipeline centers on Deramiocel (CAP-1002), an allogeneic cardiac-derived cell therapy that has demonstrated meaningful clinical efficacy in preserving cardiac and skeletal muscle function in DMD patients. As of March 2026, Capricor maintains a strong cash position of approximately $318 million, expected to support operations through 2027. The company is advancing toward a critical regulatory milestone, with the FDA currently reviewing Deramiocel's Biologics License Application (BLA) under priority review, targeting an action date of August 22, 2026. Capricor's approach represents a novel paradigm shift in DMD treatment, moving beyond traditional small-molecule and genetic therapies to leverage the immunomodulatory properties of cell-derived therapeutics.

Headquarters and Global Presence

Capricor Therapeutics is headquartered in San Diego, California, positioning the company within one of the world's most vibrant biotechnology ecosystems. The company maintains strategic partnerships and operational presence across key markets, including the United States and Japan. Through its exclusive distribution agreements with Nippon Shinyaku Co., Ltd. (trading as NS Pharma, Inc. in the United States), Capricor has secured commercial rights pathways in both the U.S. and Japanese markets for Deramiocel. The San Diego location provides proximity to leading research institutions and patient advocacy organizations focused on rare genetic diseases, supporting Capricor's clinical development and community engagement efforts. The company's geographic strategy emphasizes capturing high-value markets for orphan therapies while leveraging international partnerships to accelerate global commercialization.

Founding and History

Capricor Therapeutics was founded in 2005 as a vehicle to develop cardiosphere-derived cell (CDC) technology discovered by Dr. Eduardo Marbán at Johns Hopkins Hospital, where he served as Chief of Cardiology. The scientific foundation of Capricor's platform stems from groundbreaking research demonstrating that CDCs possess unique anti-inflammatory, anti-fibrotic, and immunomodulatory properties capable of preserving muscle function in degenerative diseases. Since the first publication describing this technology in 2007, cardiosphere-derived cells have become the subject of over 250 peer-reviewed scientific publications and have been administered to more than 250 human subjects across multiple clinical trials spanning nearly two decades. This extensive clinical validation provides strong scientific precedent for Deramiocel's safety and efficacy profile. Dr. Linda Marbán, daughter of scientific founder Dr. Eduardo Marbán, joined the company in 2005 and has served as Chief Executive Officer since November 2013, bringing deep expertise in biotechnology commercialization and rare disease development. The company went public to fund expanded clinical development and regulatory efforts, establishing Capricor as an independent publicly traded entity focused specifically on unlocking CDC technology's therapeutic potential.

Therapy Areas and Focus

Capricor's primary therapeutic focus is Duchenne muscular dystrophy (DMD), a severe X-linked neuromuscular disorder characterized by progressive muscle weakness and deterioration affecting males predominantly. DMD patients face life-threatening cardiac complications as the disease progresses, with cardiomyopathy emerging as a leading cause of morbidity and mortality in the adolescent and adult DMD population. Capricor targets the cardiac manifestations of DMD, recognizing that cardiac function is critical to disease progression and long-term survival outcomes. This represents a clinically validated unmet need, as existing therapies including corticosteroids and novel genetic approaches do not adequately address the cardiac complications driving disease progression. Beyond DMD, Capricor is developing its proprietary StealthX exosome platform technology for broader applications including vaccinology and the targeted delivery of oligonucleotides, proteins, and small-molecule therapeutics. The StealthX platform leverages engineered exosomes as delivery vehicles, capitalizing on the body's natural cellular communication mechanisms to achieve tissue-specific targeting and reduced off-target toxicity. This expansion positions Capricor to address multiple high-value therapeutic areas beyond rare muscle disease.

Technology Platforms and Modalities

Deramiocel (CAP-1002) represents an innovative allogeneic cell therapy derived from cardiosphere-derived cells (CDCs), which are rare populations of cardiac stromal cells isolated from donor hearts qualified for transplantation. These cells exert their therapeutic action through secretion of extracellular vesicles, particularly exosomes, which carry paracrine factors capable of profound immunomodulation. The mechanism of action centers on targeting tissue-resident macrophages, shifting them from pro-inflammatory M1 phenotypes toward healing-associated M2 phenotypes, thereby reducing pathological fibrosis and inflammation that characterize muscular dystrophy progression. This cell secretome-based approach represents a departure from cell replacement therapies, where functional cell engraftment is required; instead, Deramiocel's CDCs function as therapeutic factories, delivering anti-fibrotic and anti-inflammatory factors systemically through allogeneic cell transplantation. The allogeneic approach eliminates the need for patient-specific cell manufacturing, reducing complexity and manufacturing costs while enabling rapid drug distribution. Capricor's proprietary StealthX platform represents next-generation exosome technology designed for targeted delivery of therapeutic payloads including oligonucleotides, proteins, and small molecules. StealthX exosomes are engineered to evade immune recognition while optimizing tissue tropism, enabling directed delivery of cargo to specific target tissues and reducing systemic toxicity. This platform technology is currently under investigation in a Phase I NIAID-sponsored clinical trial evaluating a StealthX-based vaccine platform.

Key Pipeline and Programs

Deramiocel (CAP-1002) for Duchenne muscular dystrophy represents Capricor's most advanced program, having completed the pivotal Phase III HOPE-3 trial in December 2025. The HOPE-3 trial enrolled 106 eligible subjects in a randomized, double-blind, placebo-controlled design across multiple clinical centers, evaluating both skeletal and cardiac endpoints. The trial achieved statistical significance on its primary endpoint using the Pediatric Upper Limb assessment (PUL v2.0), demonstrating meaningful functional benefit in upper limb strength and mobility. Additionally, HOPE-3 achieved statistical significance on a pre-specified key secondary cardiac endpoint measuring left ventricular ejection fraction (LVEF), directly addressing the cardiac complications that drive mortality in DMD patients. Positive HOPE-3 results triggered FDA acceptance of Deramiocel's Biologics License Application (BLA) under priority review, with the PDUFA target action date of August 22, 2026. Deramiocel has received Orphan Drug Designation from both the U.S. FDA and European Medicines Agency (EMA), providing regulatory incentives and extended market exclusivity upon approval. The company is planning to present late-breaking clinical data from HOPE-3 at the 2026 MDA Clinical and Scientific Conference, demonstrating ongoing engagement with the neuromuscular disease community. Beyond DMD, Capricor's StealthX exosome platform is advancing in a Phase I NIAID-sponsored trial evaluating a vaccine platform, with preliminary data indicating favorable safety profiles across all dose levels tested and final results expected in second quarter 2026.

Key Personnel

Dr. Linda Marbán serves as Chief Executive Officer, a position she has held since November 2013. Dr. Marbán is also a co-founder of Capricor, Inc. (wholly-owned subsidiary) and joined the organization in 2005, bringing more than 20 years of biotechnology experience spanning research, product development, and business development. Her leadership has guided Capricor through multiple clinical inflection points and positioned the company for its critical regulatory milestone. Dr. Sanford Litvack serves as Executive Chairman, joining Capricor's board in 2012 and transitioning to Executive Chairman in November 2013, providing strategic business guidance and governance oversight. Dr. Patricia Elliott serves as Chief Operating and Science Officer, a dual-role position she assumed in 2021. In this capacity, Dr. Elliott leads product development across Capricor's therapeutic pipeline while overseeing chemistry, manufacturing, and controls (CMC) operations, manufacturing scale-up, quality assurance, and analytical and process development—critical functions for advancing Deramiocel toward commercialization. Rashid Awadalla serves as Chief Development Officer, joining Capricor in 2023 and bringing 25 years of pharmaceutical and biotechnology industry experience in product development spanning the entire drug lifecycle from early discovery through post-market surveillance. Mr. Awadalla provides strategic oversight of commercial planning and clinical development strategy. Karen G. Krasney serves as Executive Vice President and General Counsel, ensuring regulatory compliance and managing intellectual property and legal matters. AJ Bergmann serves as Chief Financial Officer, managing financial strategy, investor relations, and capital allocation.

Strategic Partnerships

Capricor has established meaningful partnerships that provide commercial, manufacturing, and clinical support. Nippon Shinyaku Co., Ltd. (operating as NS Pharma, Inc. in the United States) represents Capricor's primary commercial partner, having secured exclusive distribution rights for Deramiocel across the United States and Japan. This partnership provides Capricor with manufacturing support, regulatory expertise in Japanese markets, and commercial infrastructure for product distribution. Nippon Shinyaku participated in a registered direct offering in 2023 alongside Highbridge Capital Management, demonstrating strong financial commitment and alignment with Capricor's development strategy. Government and academic partnerships are central to Capricor's platform validation and advancement. The National Institutes of Health (NIH), through the National Institute of Allergy and Infectious Diseases (NIAID), sponsors the Phase I clinical trial evaluating Capricor's StealthX exosome vaccine platform, reflecting confidence in the platform's scientific merit and broad applicability. Additional collaborative relationships include partnerships with Johns Hopkins University (JHU), where the original CDC technology was discovered; Cedars-Sinai Medical Center (CSMC), providing clinical research infrastructure; the U.S. Department of Defense (DoD) and the U.S. Army Institute of Surgical Research (USAISR), supporting translational research. The California Institute for Regenerative Medicine (CIRM) has provided non-dilutive funding supporting early-stage research. These partnerships reflect recognition of Capricor's scientific innovation and position the company at the intersection of government-supported regenerative medicine research and commercial biotechnology development.

FAQ Section

Deramiocel is an allogeneic (non-patient-specific) cell therapy composed of cardiosphere-derived cells (CDCs) obtained from donor hearts qualified for transplantation. Unlike traditional cell replacement therapies that rely on engraftment and cell survival, Deramiocel functions as a therapeutic factory, working through paracrine secretion of extracellular vesicles and anti-inflammatory factors. The mechanism targets tissue-resident macrophages, shifting them from destructive inflammatory states toward healing-promoting phenotypes. This immunomodulation reduces pathological fibrosis and inflammation that characterize Duchenne muscular dystrophy. The allogeneic approach provides significant manufacturing advantages: a single donor heart yields millions of doses, enabling rapid distribution without requiring patient-specific cell manufacturing. Over 250 scientific publications and administration to more than 250 human subjects across decades of clinical trials provide robust scientific validation of CDCs' safety and efficacy profiles. This mechanism represents a novel paradigm in DMD treatment, distinct from genetic therapies and traditional small-molecule approaches.

The pivotal Phase III HOPE-3 trial, completed in December 2025, enrolled 106 eligible DMD patients in a randomized, double-blind, placebo-controlled design across multiple clinical centers. HOPE-3 achieved statistical significance on its primary efficacy endpoint using the Pediatric Upper Limb assessment (PUL v2.0), demonstrating that Deramiocel meaningfully improves upper limb strength, function, and mobility—clinically meaningful outcomes for DMD patients facing progressive functional decline. Crucially, HOPE-3 also achieved statistical significance on a pre-specified key secondary endpoint measuring left ventricular ejection fraction (LVEF), directly demonstrating cardiac benefit. This cardiac endpoint is particularly significant because cardiomyopathy-driven complications represent a leading cause of morbidity and mortality in adolescent and adult DMD patients. The robust efficacy results across both skeletal and cardiac domains position Deramiocel as addressing a major unmet clinical need. These positive topline results triggered FDA acceptance of Deramiocel's Biologics License Application (BLA) under priority review status, with a target FDA action date of August 22, 2026, creating potential for approval and market availability by mid-2026.

Deramiocel (CAP-1002) has achieved multiple important regulatory milestones. The therapy received Orphan Drug Designation from both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), providing regulatory incentives including extended market exclusivity and priority review. Following announcement of positive HOPE-3 Phase III results in December 2025, the FDA accepted Deramiocel's Biologics License Application (BLA) for review under priority review designation, accelerating the review timeline. The PDUFA target action date is August 22, 2026, meaning the FDA aims to issue a complete response letter or approval decision by this date. Priority review designation (standard review is typically 10 months; priority is 6 months) reflects FDA recognition of Deramiocel's potential to address serious, life-threatening disease. Capricor is concurrently building commercial infrastructure with partner Nippon Shinyaku and manufacturing the drug substance and drug product to meet anticipated approval timelines. The combination of Orphan Drug Designation's extended market exclusivity, strong efficacy data, and FDA priority review positioning creates favorable regulatory momentum toward approval in 2026.

StealthX is Capricor's proprietary next-generation exosome engineering platform designed for targeted therapeutic delivery. Exosomes are small extracellular vesicles (50-200 nanometers) naturally secreted by cells and serving as mediators of intercellular communication. The StealthX platform engineers these naturally-occurring exosomes to overcome traditional delivery challenges: immune evasion (enabling repeat dosing without neutralizing antibody development), tissue-specific targeting (directing therapeutic payloads to disease sites while minimizing off-target toxicity), and cargo versatility (enabling delivery of oligonucleotides, proteins, small-molecule drugs, and other modalities). This broad-spectrum delivery platform has potential applications well beyond DMD. Currently, a Phase I clinical trial sponsored by the National Institute of Allergy and Infectious Diseases (NIAID) is evaluating a StealthX-based vaccine platform, with preliminary data demonstrating favorable safety across all tested doses. Final results from this Phase I trial are expected in second quarter 2026. The platform's flexibility positions Capricor to address multiple therapeutic areas including infectious disease (vaccines), cardiovascular disease, oncology, and neurological disorders—effectively creating a technology platform with multi-billion-dollar addressable market potential.

Capricor has assembled partnerships addressing commercial, manufacturing, and clinical development needs. Nippon Shinyaku Co., Ltd. (operating as NS Pharma, Inc. in North America) holds exclusive worldwide distribution rights for Deramiocel in the United States and Japan under long-term commercialization and distribution agreements. Nippon Shinyaku brings manufacturing expertise, regulatory knowledge in Japanese markets, and commercial infrastructure enabling efficient product distribution. The company participated in a 2023 registered direct offering alongside Highbridge Capital Management, providing $23 million in capital and demonstrating strong financial commitment to Capricor's success. Government partnerships are equally important: the National Institute of Allergy and Infectious Diseases (NIAID) sponsors Capricor's Phase I StealthX vaccine trial, providing federal validation and non-dilutive funding. Academic partnerships with Johns Hopkins University (site of the original CDC discovery), Cedars-Sinai Medical Center, and the U.S. Army Institute of Surgical Research provide clinical research infrastructure and translational support. The California Institute for Regenerative Medicine (CIRM) has provided non-dilutive funding for early-stage research. These partnerships collectively provide Capricor with global commercialization reach, manufacturing scale-up support, scientific validation from top-tier institutions, and government endorsement—critical infrastructure for a late-stage biotech company transitioning toward market approval.

Duchenne muscular dystrophy is a severe, X-linked genetic disorder caused by mutations in the dystrophin gene, affecting males predominantly with incidence of approximately 1 in 3,500 male births. DMD is characterized by progressive, irreversible muscle degeneration beginning in early childhood, causing loss of ambulation typically by age 12-13. As patients enter adolescence and adulthood, the disease extends beyond skeletal muscle, causing cardiac complications including dilated cardiomyopathy that emerges as a leading cause of morbidity and mortality. DMD represents a devastating disease with profound unmet clinical need: while corticosteroids slow progression and genetic therapies address specific mutation subtypes, no approved therapy adequately addresses the cardiac manifestations driving disease progression in the broader DMD population. Approximately 20,000 to 30,000 DMD patients exist in developed markets, creating focused but high-value orphan indications. The significant life-impact and mortality risk create strong incentive for patients, families, and healthcare systems to adopt effective therapies. Capricor's focus on cardiac complications directly addresses the mechanism driving mortality, distinguishing Deramiocel from existing approaches. Orphan Drug Designation provides extended market exclusivity (7 years in the U.S. post-approval) and potential pricing premiums reflecting the serious, unmet nature of the disease, creating substantial economic value even in a focused patient population.

As of the end of 2025 and reported in March 2026 financial updates, Capricor maintains a strong cash balance of approximately $318 million, expected to support ongoing operations, clinical development, and commercial preparation through 2027. This substantial cash position was accumulated through multiple financing mechanisms: approximately $300 million in equity capital raised through private placements and public offerings; approximately $100 million in non-dilutive funding from government sources (NIH, CIRM) and strategic partners (Nippon Shinyaku); and additional funding from registered direct offerings. The $318 million cash balance is sufficient to fund: completion and analysis of HOPE-3 Phase III data; pursuit of FDA approval and potential label expansion studies; StealthX platform advancement through Phase II development; manufacturing scale-up and commercial preparation for Deramiocel's anticipated 2026 market launch; and corporate infrastructure supporting approximately 100+ employees. This financial runway extends beyond the critical FDA decision date of August 22, 2026, providing runway into 2027 and potentially enabling the company to reach significant inflection points including FDA approval and initial commercial revenue. The company's ability to self-fund major development milestones reduces dependence on external financing, providing strategic flexibility and protecting shareholder value.

Want to Update your Company's Profile?